Skip to main content
S&P 5007,659.44-1.09%DOW52,002.41-0.34%NASDAQ26,140.03-2.14%BTC$82,256.00+0.12%ETH$2,420.83-0.06%GOLD$4,188.60+0.18%OIL$98.44-0.59%
Smart Investors Daily
SID Premium
PM

NASDAQ · PMN

ProMIS Neurosciences, Inc.

Healthcare · Biotechnology

$8.15

Down-$0.55 (-6.32%)

Updated Oct 19, 2026, 10:31 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
11.34M
P/E ratio
-0.41
Dividend yield
0.00%
52-week range
$6.27 – $27.40
Volume
20.42K
Avg. volume
31.52K

Price performance · PMN

PMN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 16, 2026

PMN closed at $8.15 after 20 trading sessions, down 40.21% for the selected period.

Last close
$8.15
Period change
-40.21%
Period low
$8.15
Period high
$13.63
Daily close
View OHLC price history
PMN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 16, 2026$8.89$9.64$7.935$8.1520.42K
Oct 15, 2026$8.29$8.87$8.00$8.7033.54K
Oct 14, 2026$8.41$8.81$8.16$8.28523.38K
Oct 13, 2026$9.38$9.47$8.51$8.6627.13K
Oct 12, 2026$9.61$9.78$9.20$9.4523.73K
Oct 9, 2026$9.06$10.15$9.06$9.6118.85K
Oct 8, 2026$9.02$9.3692$8.78$9.1535.27K
Oct 7, 2026$9.17$9.5199$9.01$9.1225.17K
Oct 6, 2026$9.46$9.516$8.775$9.2126.46K
Oct 5, 2026$9.50$9.77$9.07$9.3738.21K
Oct 2, 2026$9.44$10.38$9.16$9.4027.81K
Oct 1, 2026$10.98$10.98$9.21$9.38102.14K
Sep 30, 2026$10.68$11.3235$10.42$10.8512.68K
Sep 29, 2026$10.56$11.10$10.525$10.63516.94K
Sep 28, 2026$11.15$11.57$10.51$10.6525.06K
Sep 25, 2026$12.06$12.06$11.15$11.2720.1K
Sep 24, 2026$12.83$13.06$11.29$11.5752.7K
Sep 23, 2026$13.45$13.7816$12.94$12.9443.69K
Sep 22, 2026$13.80$14.22$13.45$13.5894.2K
Sep 21, 2026$13.54$14.22$13.13$13.6326.24K

Latest PMN news

The latest Smart Investors Daily articles mentioning PMN.

Stock researchCompany · Overview

PMN research

Overview

Company profile and research snapshot.

Company profile

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.00
Implied upside
—
Analysts
—
PMN recent ratings
DateFirmRatingTarget
Aug 14, 2026GuggenheimBuy—
Jul 29, 2026GuggenheimBuy—
Jul 28, 2026Chardan CapitalBuy—
Jul 27, 2026Chardan CapitalBuy—
Jul 8, 2026Roth CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 6, 2026

ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

Former senior Biogen and Roche executive brings deep experience across Alzheimer’s clinical development, launch readiness, commercialization and global medical strategy Appointment strengthens commercial and development leadership as PMN310 advances toward 12-month topline data expected in Q1 2027 CAMBRIDGE, Mass.,, Oct. 06, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology company developing therapeutics targeting toxic

Yahoo · Sep 1, 2026

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings. Conference details below: September 9-11: Cantor Global Healthcare ConferenceLocation: New York, NYFires

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By